Edesa Biotech Stock News

Amid a soft opening performance for the major equity indices, Edesa Biotech (NASDAQ: EDSA ) shot up 7% against the prior session before dipping into negative territory during the afternoon session. Th

TORONTO, ON / ACCESSWIRE / September 8, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that P

TORONTO, ON / ACCESSWIRE / July 11, 2022 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par N

TORONTO, ON / ACCESSWIRE / May 19, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par Ni

Edesa is one of 4 pharmaceutical companies that received a grant from the Canadian government to develop a drug to treat COVID-19. EB01 achieved all endpoints in phase 2 clinical trial in the treatmen

Health Canada has approved to test Edesa Biotech Inc''s (NASDAQ: EDSA ) monoclonal antibody candidate, designated EB05, as COVID-19 rescue therapy for critically ill patients in the Phase 3 part of a Phase 2/3 clinical study. Approval of the company''s Phase 3 study design follows favorable Phase 2 results, demonstrating preliminary evidence of EB05''s ability to reduce mortality in Full story available on Benzinga.com

Edesa Biotech (EDSA) has received approval from Health Canada to test its monoclonal antibody candidate, designated EB05, as a rescue therapy for critically ill patients in Phase 3 part

Health Canada has approved to test Edesa Biotech Inc's (NASDAQ: EDSA) monoclonal antibody candidate, designated EB05, as COVID-19 rescue therapy for critically ill patients in the Phase 3 part of a

HC Wainwright initiated coverage on shares of Edesa Biotech (NASDAQ:EDSA) in a report published on Monday, Analyst Ratings Network reports. The brokerage issued a buy rating and a $16.00 price target on the stock. Shares of EDSA stock opened at $6.12 on Monday. Edesa Biotech has a 52 week low of $4.05 and a 52 []

Brokerages expect Edesa Biotech, Inc. (NASDAQ:EDSA) to announce earnings of ($0.37) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Edesa Biotechs earnings. The highest EPS estimate is ($0.27) and the lowest is ($0.42). Edesa Biotech reported earnings of ($0.22) per share in the same quarter []

Edesa Biotech (NASDAQ:EDSA) and Dyne Therapeutics (NASDAQ:DYN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk. Volatility & Risk Edesa Biotech has a beta of 0.59, suggesting that its share price [] The post Edesa Biotech (NASDAQ:EDSA) and Dyne Therapeutics (NASDAQ:DYN) Financial Survey appeared first on ETF Daily News .

Equities analysts forecast that Edesa Biotech, Inc. (NASDAQ:EDSA) will report earnings per share (EPS) of ($0.35) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Edesa Biotechs earnings. The highest EPS estimate is ($0.27) and the lowest is ($0.42). Edesa Biotech posted earnings of ($0.22) per share during the same []

Vanguard Group Inc. raised its stake in Edesa Biotech, Inc. (NASDAQ:EDSA) by 88.9% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 109,158 shares of the companys stock after buying an additional 51,369 shares during the quarter. Vanguard Group Inc. owned approximately 0.82% of Edesa Biotech worth $576,000 []

Edesa Biotech Inc (NASDAQ: EDSA) has announced additional results from the Phase 2 part of an ongoing Phase 2/3 study of EB05 as a single-dose treatment for hospitalized COVID-19 patients. Related: �

Edesa Biotech Inc (NASDAQ: EDSA) is trading higher Tuesday after the company announced additional results from the Phase 2 part of the ongoing Phase 2/3 study of EB05 in COVID-19.  Edesa reported th